Physician profile
Brian Hunis
NPI 1972796159
$16,135.29
in general payments reported to CMS, 2019-2025
21 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.58 · 2021: $31.19 · 2022: $123 · 2023: $207 · 2024: $3,825 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,468 · Honoraria: $3,425 · Travel and Lodging: $1,761 · Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,467.50 |
| Honoraria | $3,425.00 |
| Travel and Lodging | $1,761.33 |
| Food and Beverage | $1,258.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,217.13 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Novocure INC. | $3,631.97 | 2023-2024 | Optune Lua (Novottf-200t) |
| Gilead Sciences, INC. | $1,134.99 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $1,087.50 | 2025 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $400.00 | 2024 | Imfinzi |
| Caris Mpi, INC. | $258.84 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $201.62 | 2025 | Xt Cdx |
| Coherus Oncology, INC. | $47.91 | 2022 | |
| Genentech USA, INC. | $35.80 | 2022 | |
| Pfizer INC. | $29.52 | 2025 | |
| Celgene Corporation | $20.55 | 2019 | |
| G1 Therapeutics, INC. | $20.15 | 2022 | |
| Merck Sharp & Dohme LLC | $18.71 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.23 | 2019 | |
| Karyopharm Therapeutics INC. | $12.37 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hunis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.